bioAffinity Technologies will present CyPath Lung clinical and veteran-focused research at NAVREF, including previously reported results showing 92% sensitivity, 87% specificity and 99% negative predictive value. The presentations matter to investors because they cover clinical use, an enrolling military and veteran study, and the diagnostic’s stated role alongside other evaluations.
Key Highlights
- NAVREF’s annual conference will take place September 27, 2026, in Arlington, Virginia.
- The FlowPath Lung study is enrolling veterans and military personnel and has support from the John P. Murtha Cancer Center Research Program.
- Presentations will address CyPath Lung’s clinical and research use in veteran and military populations.
The event is scheduled for September 27, 2026, in Arlington, Virginia. The presentations will address the diagnostic’s use in clinical practice and research involving veteran and military populations.
CyPath Lung Cases and FlowPath Study bioAffinity Technologies, Inc.
(NASDAQ: BIAF) says the approach accelerated diagnosis, supported difficult clinical discussions and helped avoid unnecessary invasive procedures. A separate poster covers the ongoing FlowPath™ Lung research study evaluating the test in veteran and military populations. FlowPath Lung uses the same test as commercially available CyPath Lung, with the name reserved for the research programme. The study is currently enrolling, while the John P. Murtha Cancer Center Research Program is providing support and partial funding.
At-Home Collection and Clinical Performance
CyPath Lung’s at-home sputum collection is highlighted as a way for participants to provide specimens without travelling to a VA medical facility. The test uses flow cytometry and automated analysis to identify cell populations in sputum associated with malignancy.
FAQs
Q: When and where will bioAffinity Technologies present CyPath Lung data?
A: BioAffinity Technologies will present the data at the NAVREF Annual Conference in Arlington, Virginia. The conference begins September 27, 2026.
Q: What is the FlowPath Lung study evaluating?
A: FlowPath Lung evaluates the CyPath Lung flow cytometry test in veteran and military populations. Its study name is used exclusively for this research programme.
Q: How is CyPath Lung marketed?
A: The article does not state how CyPath Lung is marketed. It states only that CyPath Lung is commercially available and uses at-home sputum collection.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.